SEC Form 3 · accession 0002141590-26-000006
Attovia Therapeutics, Inc. · ATTO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Zaneta Odrowaz
Officer — Chief Business Officer
Period of report
Aug 4, 2026
Accepted (ET)
Aug 4, 2026 · 7:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0002058707
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 103,269 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.5793 | holding | — | — | — | — | Aug 16, 2033 | Common Stock | 15,137 | — | D |
| Stock Option (Right to Buy)F3 | $2.8799 | holding | — | — | — | — | Mar 5, 2034 | Common Stock | 5,382 | — | D |
| Stock Option (Right to Buy)F4 | $3.5302 | holding | — | — | — | — | May 8, 2034 | Common Stock | 102,260 | — | D |
| Stock Option (Right to Buy)F5 | $4.9237 | holding | — | — | — | — | May 17, 2035 | Common Stock | 85,037 | — | D |
Explanation of responses
- F1As of the date of this Form 3, 17,156 shares are unvested. The remaining shares will continue to vest monthly and will be fully vested on April 27, 2027, subject to continued service to the Issuer through each vesting period.
- F2The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares underlying the option vested on August 17, 2024, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the reporting person's continued service to the Issuer on each vesting date.
- F3The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares underlying the option vested on March 6, 2025, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the reporting person's continued service to the Issuer on each vesting date.
- F4The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares underlying the option vested on May 9, 2025, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the reporting person's continued service to the Issuer on each vesting date.
- F5The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares underlying the option vested on May 18, 2026, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the reporting person's continued service to the Issuer on each vesting date.